OrbiMed Advisors LLC is a healthcare-focused investment firm founded in 1989, managing approximately $5 billion in assets. The firm specializes in a range of investment strategies, including private equity, venture capital, and public equity, targeting companies across the healthcare spectrum—from startups to large multinational corporations. OrbiMed invests in various sectors within the healthcare industry, including pharmaceuticals, biotechnology, life sciences, medical devices, and health IT. The firm typically invests between $3 million and $150 million, often seeking majority stakes in its portfolio companies. With a global investment approach, OrbiMed operates from offices in New York, San Francisco, Mumbai, Herzliya, Shanghai, West Kowloon, and Luxembourg, focusing on opportunities in North America, Europe, Asia, and Israel. Its investment strategies are underpinned by fundamental analysis, encompassing investments in public equity, fixed income, and alternative markets.
Garuda Therapeutics is a biotechnology company focused on creating off-the-shelf hematopoietic stem cell therapies aimed at treating various severe and life-threatening conditions. The company specializes in addressing blood, bone marrow, immune, and metabolic diseases. By leveraging expertise in innovative research methods, including the use of zebrafish, mice, and human-induced pluripotent stem cells, Garuda analyzes novel genes and mechanisms vital for blood formation. This approach enables the development of mechanism-based therapies designed to improve patient outcomes.
Caris Molecular Intelligence revolutionizes precision medicine to provide physicians and patients with information about their health. They develop Caris Molecular Intelligence Services that does panomic molecular profiling for oncology.
Caris Life Sciences was founded with a very simple but powerful purpose – to help improve the lives of as many people as possible. Through tireless efforts, breakthrough molecular science, and a passionate commitment to quality, they remain steadfastly focused on the most important part of their work – the patient.
It was founded in 1996 and is based in Irving, Texas.
Capstan Therapeutics is advancing precision in vivo cell engineering to develop therapeutics for a broad range of disease categories with unmet or underserved clinical need.
ACELYRIN is a biopharma company focused on providing patients life-changing new treatment options by identifying, acquiring, and accelerating the development and commercialization of promising drug candidates and by leveraging its expertise to rapidly advance these medicines to patients.
Adaptive Biotechnologies is a commercial-stage company focused on advancing immune-driven medicine by leveraging the biology of the adaptive immune system for disease diagnosis and treatment. Founded in 2009 and headquartered in Seattle, Washington, the company offers a range of products and services, including the immunoSEQ research service and kit, which aids in research and the discovery of diagnostic signals. Its FDA-authorized clonoSEQ diagnostic test is designed for the detection and monitoring of minimal residual disease in patients with specific blood cancers. Additionally, Adaptive Biotechnologies is developing a pipeline of clinical products aimed at diagnosing and treating cancer, autoimmune conditions, and infectious diseases. The company has formed strategic collaborations with notable partners, including Genentech for neoantigen-directed T cell therapies, Microsoft for early disease detection tests from blood samples, and Amgen for therapeutic development related to COVID-19.
Delfi Diagnostics, Inc. is a biotechnology company based in Baltimore, Maryland, that specializes in early cancer detection through non-invasive blood tests. Founded in 2018, the company utilizes advanced artificial intelligence and genome sequencing technologies to identify unique patterns of DNA fragmentation in patients' blood, enabling the detection of cancer at its most treatable stage. By focusing on precision diagnostics, Delfi Diagnostics aims to improve patient outcomes and contribute to the evolving landscape of cancer care.
X4 Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on developing innovative therapeutics for primary immune deficiencies and cancer. The company's lead drug candidate, mavorixafor, is an oral small molecule antagonist of the CXCR4 chemokine receptor, currently undergoing various clinical trials. Mavorixafor is in Phase III trials for treating patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome, and is also being tested in Phase Ib trials for severe congenital neutropenia and Waldenström macroglobulinemia, alongside a Phase IIa trial for clear cell renal cell carcinoma. Additionally, X4 Pharmaceuticals is advancing X4P-002, aimed at treating glioblastoma multiforme, and is developing X4P-003 for primary immune deficiencies. The company has established a license agreement with Abbisko Therapeutics to explore the use of mavorixafor in combination with checkpoint inhibitors for oncology applications. Founded in 2014, X4 Pharmaceuticals was previously known as Arsanis, Inc. before rebranding in March 2019.
MiroBio Ltd develops and manufactures antibody modulators of immune cell receptors for auto-immune diseases. The company is developing antibodies and variants to
stimulate specific immune cell signals to harness the natural control mechanisms of the immune system. The company was incorporated in 2018 and is headquartered in Oxford, United Kingdom.
Frontera Therapeutics is an AAV gene therapy company with the mission to establish a low-cost and scalable platform, to develop and produce high-quality and affordably priced rAAV therapies for the global market.
Aerin Medical Inc. is a health technology company based in Sunnyvale, California, focused on developing non-invasive treatment solutions for nasal breathing disorders. Founded in 2011, the company specializes in therapeutic devices that utilize low-power radiofrequency energy to remodel nasal soft tissues, effectively addressing the underlying causes of conditions such as nasal obstruction and chronic rhinitis. Aerin Medical offers procedures and devices, including the VivAer procedure and the RhinAer procedure, along with their corresponding styluses, which allow ENT physicians to treat nasal airway conditions in an office setting under local anesthesia. These innovative solutions aim to improve patient outcomes by providing safe, quick, and effective relief from chronic nasal symptoms while minimizing downtime.
DarioHealth Corp. is a digital health company focused on developing and commercializing proprietary technologies that enable consumers to conduct laboratory testing using smartphones and mobile devices. Its primary product, the Dario Smart Diabetes Management Solution, integrates a mobile application with a pocket-sized blood glucose monitoring device. This real-time, cloud-based solution assists users in managing their diabetes by offering features such as monitoring of chronic conditions, coaching, digital communication, and real-time alerts for trends and patterns. DarioHealth markets its products through direct consumer sales, retail pharmacies, hospitals, distributors, and online platforms. The company, originally known as LabStyle Innovations Corp., was founded in 2011 and is headquartered in Caesarea, Israel.
Upstream Bio is a clinical-stage biotechnology company established in 2004 and headquartered in the United States. The company specializes in developing antibody therapies aimed at treating inflammatory diseases, with a primary focus on severe respiratory disorders, particularly severe asthma. Upstream Bio is advancing its lead candidate, verekitug, an antagonist that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine known to play a significant role in driving inflammatory responses. The approach of targeting TSLP positions Upstream Bio to address various immune-mediated conditions by intervening at a crucial point in the signaling pathways involved in inflammation.
Aspen Neuroscience, Inc. is a private biotechnology company based in San Diego, California, focused on developing innovative therapies for neurological conditions, particularly Parkinson's disease. Established in 2018, the company utilizes induced pluripotent stem cells to create patient-specific restorative cell therapies. Its product pipeline includes ANPD001, an autologous neuron replacement therapy designed for sporadic Parkinson's disease, and ANPD002, a gene-edited version aimed at familial forms of the disease. Aspen Neuroscience combines genomic approaches with stem cell biology to advance its mission of modifying the course of Parkinson's disease through these novel therapeutic strategies.
Valneva SE is a biotechnology company focused on developing and commercializing vaccines for infectious diseases that lack effective solutions. It offers two commercial vaccines for travelers: IXIARO/JESPECT, which prevents Japanese encephalitis, and DUKORAL, aimed at preventing cholera and certain types of diarrhea. The company is also advancing a pipeline of vaccines, including a candidate targeting Lyme disease and a single-shot vaccine for chikungunya. Valneva operates in several countries, including Austria, Canada, France, Sweden, the United Kingdom, and the United States. Established in 1999 and headquartered in Nantes, France, Valneva collaborates with Dynavax Technologies Corporation to enhance vaccine development efforts, particularly in response to COVID-19.
Electra Therapeutics is a clinical-stage biotechnology company focused on developing therapies that target signal regulatory proteins (SIRP) for treating immunological diseases and cancer. The company has one program in clinical development and two additional preclinical programs. Its lead product candidate, ELA026, is a monoclonal antibody designed to target SIRP on the surface of myeloid and T cells, effectively depleting pathological immune cells. ELA026 is currently being investigated for secondary hemophagocytic lymphohistiocytosis (sHLH), a severe hyperinflammatory condition for which no approved treatment exists.
Congruence Therapeutics operates as a biotechnology company working at the interface of computational and experimental drug discovery to design novel small molecules for diseases of protein misfolding.
HanBio Therapeutics
Series A in 2022
HanBio Therapeutics is a biotechnology company committed to researching and developing next generation transformative medicines.
ImmPACT Bio USA Inc. is a cell therapy company aiming to develop potent and selective engineered T-cells for the treatment of solid tumors. The Company's technology enables targeting loss-of-gene features of solid tumor cells, sparing normal, healthy tissues.
Alterome Therapeutics is a precision oncology biotech developing alteration-specific therapeutics to address high value and validated oncogenic drivers.
TandemAI is an advanced technology company dedicated to reinventing drug discovery infrastructure. The company integrates proprietary AI-driven, high-performance computation with its efficient, large-scale in-house wet lab operations to deliver a turnkey drug discovery solution.
Odyssey Therapeutics is a biotechnology company pioneering the efficient development of next-generation immunomodulators and oncology medicines. Odyssey is making a transformational impact on the field of drug discovery and is accelerating the path to clinical development to drive the creation of more effective precision medicines.
Emergence Therapeutics AG develops novel antibody drug conjugate (ADC) immuno-therapeutics to treat high need cancers. The company was incorporated in 2019 and is based in Duisburg, Germany.
Cyrus Biotechnology builds software tools to accelerate basic research in biotech, pharma, and industrial biotechnology. Cyrus Bench delivers an enterprise version of the Rosetta molecular modeling and design toolkit, with the associated array of bio-molecular computation tools.
It was founded in 2014 and headquartered in Seattle, Washington.
Alpheus Medical provides a novel sonodynamic therapy platform targeting solid body cancers. Alpheus Medical also provides a non-invasive drug-device combination for outpatient treatment of recurrent glioblastoma multiforme (rGBM).
ACELYRIN is a biopharma company focused on providing patients life-changing new treatment options by identifying, acquiring, and accelerating the development and commercialization of promising drug candidates and by leveraging its expertise to rapidly advance these medicines to patients.
Tricida, Inc. is a pharmaceutical company based in South San Francisco, California, established in 2013. The company is dedicated to the development and commercialization of its lead product candidate, TRC101, a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease (CKD). Metabolic acidosis, a condition often associated with CKD, can hasten kidney deterioration and lead to serious complications such as muscle wasting and loss of bone density. Tricida has successfully completed a Phase 3, double-blind, placebo-controlled trial of TRC101, which aims to bind and remove acid from the gastrointestinal tract, thereby addressing the underlying metabolic issues and potentially slowing the progression of CKD.
Edge Medical Robotics, Inc. is a company that specializes in designing and developing advanced surgical equipment. Founded on May 4, 2017, and based in Longgang, Shenzhen, China, the company is dedicated to researching and promoting cutting-edge medical technology. Its mission focuses on enhancing surgical safety and treatment efficacy, aiming to elevate the overall standards of healthcare. Through a commitment to excellence and precision in product development, Edge Medical Robotics strives to contribute positively to the improvement of social health outcomes.
PierianDx, Inc. is a technology company that develops a genomic software-as-a-service (SaaS) solution designed to manage, analyze, and interpret complex genomic tests for clinical laboratories in the United States. The company offers the Clinical Genomicist Workstation, a platform that streamlines the workflow for patient cases, handling everything from sequencing and analysis to report generation and integration with electronic health records. PierianDx aims to enhance the adoption of genomic sequencing in healthcare, enabling physicians to diagnose and treat patients with cancer and other complex diseases more effectively. The company also provides consulting and technical services to support its clients, which include health systems, children's hospitals, comprehensive cancer centers, and reference laboratories. Founded in 2014 and headquartered in Saint Louis, Missouri, PierianDx has established itself as a trusted source for advanced genomic reporting and decision support in clinical care.
ReCode Therapeutics is a development-stage biopharmaceutical company focused on the correction of the nonsense mutations that account for 1/3 of all inherited diseases, including approximately 10% of cystic fibrosis. They have combined selected tRNAs with their unique and diverse proprietary delivery platforms to create and develop first-in-class suppressor tRNA-nanoparticle therapeutics for correcting nonsense mutations. ReCode’s diverse pipeline includes lead programs for primary ciliary dyskinesia (PCD) and nonsense mutations in cystic fibrosis (CF). The company’s proprietary non-viral lipid nanoparticle platform enables the delivery of a variety of payloads, and precise organ targeting of nucleic acid and protein payloads via both systemic and local delivery. ReCode is leveraging its nanoparticle and nucleic acid technologies across multiple modalities, including mRNA-mediated protein replacement therapies, first-in-class tRNA NanoCorrectors for diseases caused by nonsense mutations, and gene editing. The company was founded in 2015 and is based in Dallas, Texas.
Scout Bio, Inc. researches and develops one-time therapies for major chronic pet health conditions using veterinary biotechnology and gene therapy. It offers therapies for anemia associated with chronic kidney disease (CKD) in cats. The company offers pet therapeutics, including small molecular drugs, protein therapies, and gene therapies. Scout Bio, Inc. was founded in 2016 and is headquartered in Philadelphia, Pennsylvania.
PharmEasy is a leading pharmacy aggregator in India that operates an online drug delivery platform aimed at enhancing the supply chain of pharmaceuticals. By digitizing the process, it connects patients with local pharmacy stores and diagnostic centers, ensuring they can easily access a wide range of medicines and healthcare products. The platform is designed to make healthcare services more accessible and affordable, emphasizing the importance of good health for everyone. Through its services, PharmEasy strives to simplify the healthcare experience for patients, allowing them to fulfill their medical needs efficiently.
Garuda Therapeutics is a biotechnology company focused on creating off-the-shelf hematopoietic stem cell therapies aimed at treating various severe and life-threatening conditions. The company specializes in addressing blood, bone marrow, immune, and metabolic diseases. By leveraging expertise in innovative research methods, including the use of zebrafish, mice, and human-induced pluripotent stem cells, Garuda analyzes novel genes and mechanisms vital for blood formation. This approach enables the development of mechanism-based therapies designed to improve patient outcomes.
LifeCell is a private stem cell bank that brings the concept of umbilical cord stem cell banking to India. Set up in the year 2004, LifeCell started out as an umbilical cord stem cell banking company and has now grown to become a comprehensive stem cells solutions provider with a complete spectrum of services including multi-service stem cell banking, R&D, stem cell clinical trials, and stem cell therapy. Based in Chennai, LifeCell has a spread over 100 service centers in India and the GCC countries.
Ventyx Biosciences, Inc. is a biotechnology company based in Encinitas, California, focused on developing selective inhibitors of TYK2 for the treatment of autoimmune diseases. Incorporated in 2018, the company boasts a diverse portfolio of innovative clinical and pre-clinical programs aimed at high-value therapeutic targets. Through its research and development efforts, Ventyx is committed to advancing treatments that address unmet medical needs in the autoimmune disease space.
Amolyt Pharma is a clinical-stage biotechnology company focused on developing peptide-based therapies for rare endocrine and metabolic disorders. The company's leading programs include AZP-3601, a parathyroid hormone analog aimed at treating hypoparathyroidism by maintaining sustained calcium levels in the blood, and AZP-3404, which features a novel mechanism of action that may help restore fat and glucose metabolism. Through its innovative approach, Amolyt Pharma seeks to provide effective treatments for patients suffering from critical and rare metabolic conditions.
Alpine Immune Sciences is a clinical-stage biopharmaceutical company based in Seattle, Washington, specializing in the discovery and development of protein-based immunotherapies aimed at treating autoimmune and inflammatory diseases, as well as cancer. Founded in 2015, the company leverages a proprietary scientific platform that transforms native immune system proteins into innovative, multi-targeted therapeutics. Its lead candidates include ALPN-101, an antagonist targeting the inducible T cell costimulator (ICOS) for autoimmune disorders, and ALPN-202, which functions as an antagonist of programmed cell death protein ligand 1 (PD-L1) and cytotoxic T-lymphocyte associated protein 4 (CTLA-4) for cancer treatment. Additionally, Alpine has established a collaboration with Kite Pharma to develop therapies that engage the immune synapse for cancer treatment.
ADARx Pharmaceuticals is a genetic medicine company focusing on the base editing of mRNA transcripts. It discovers and develops innovative therapeutics that can utilize a family of endogenous enzymes called adenosine deaminase acting on RNA (ADAR) to precise target and correct single point mutations on an mRNA, thus the production of desired and functional protein is restored.
It was founded in 2019 and is headquartered in San Diego, California.
Disc Medicine, Inc. is a biotechnology company focused on developing therapeutics based on human genetics to address ineffective red blood cell production in hematologic diseases. The company specializes in programs targeting the hepcidin metabolism axis for the treatment of disorders related to hepcidin. Founded in 2017 and headquartered in Cambridge, Massachusetts, Disc Medicine is led by a team of experienced scientists and industry experts, supported by a panel of advisors with a proven history in discovering and developing innovative therapies. The company was established with backing from Atlas Venture, along with contributions from Novo Ventures and Access Biotechnology.
Humacyte, Inc. is a medical research and development company headquartered in Morrisville, North Carolina, established in 2004. The company specializes in creating human tissue-based products aimed at regenerative medicine and vascular surgery. Its core technology involves the design of acellular extracellular matrices derived from banked vascular smooth muscle cells, which are decellularized to minimize the risk of rejection. These innovations are utilized to produce tissue-engineered grafts for patients requiring vascular repair or replacement, positioning Humacyte as a key player in addressing vascular diseases and enhancing surgical outcomes.
Neurogastrx, Inc. is a venture-stage biopharmaceutical company focused on developing products for gastrointestinal disorders. Established in 2017 and headquartered in Campbell, California, the company is known for its innovative product NG101, which aims to enhance gastric motility and possesses antiemetic properties.
Vigil will use the Series A funds to progress its lead pipeline candidate, a monoclonal antibody TREM2 agonist, through Phase 1 studies, advance their small molecule TREM2 agonist to IND, as well as pursue additional assets to grow the pipeline and increase the body of data supporting microglia biology as an important therapeutic pathway.
Carrot offers a fertility benefit for modern companies, focused on making fertility care easier, accessible, and more affordable. The company partners with modern companies to provide fertility coverage for the millions of employees. Through its software, Carrot helps employees to personalize a fertility plan, chat with fertility experts, order medications, and access unique content. It helps them access the care they need, such as egg freezing, in-vitro fertilization, fertility diagnoses, and more.
GentiBio, Inc. is a biotherapeutics company focused on developing engineered regulatory T cells (EngTregs) to treat a range of conditions, including autoimmune, alloimmune, autoinflammatory, and allergic diseases. Founded in 2020 and based in Boston, Massachusetts, with additional locations in Seattle and Israel, GentiBio utilizes a proprietary platform that combines autologous and allogeneic EngTregs. This innovative approach aims to restore immune tolerance and address the limitations found in current regulatory T-cell therapies. The company was co-founded by experts in Treg biology and synthetic immunology, emphasizing its commitment to addressing the underlying causes of diseases linked to immune system dysfunction.
XtalPi Inc. is a pharmaceutical technology company founded in 2014 and headquartered in Cambridge, Massachusetts, with additional offices in China. The company specializes in leveraging artificial intelligence and advanced computing to accelerate drug development. Its offerings include XtalForc, a visual force field calculation software; XtalVision, a tool for crystal structure prediction; and Renova, which supports AI-driven research and development. XtalPi provides a range of services such as crystal structure prediction and determination, solid state testing and analysis, crystallization process development, and small molecule drug design. By collaborating with pharmaceutical companies, XtalPi uses its predictive algorithms to facilitate the development of new drugs and the creation of patents, enhancing the efficiency of the drug discovery process.
Rimag provides medical imaging service. The company engages in medical imaging center operation, relevant cloud technology development, and talent training. The company was founded in 2014 and is based in Shenzhen, China.
Zentera Therapeutics
Series B in 2021
Zentera Therapeutics is a biopharmaceutical company.
Miaoshou Doctor is a healthcare service platform for building an online communication service platform between patients and doctors. It helps healthcare professionals and patients to manage post-diagnosis outcomes and allows doctors to actively follow up with their patient's health through additional counseling and prescriptions. Tao He and Daoliang Han founded the company in 2015 and is based in Beijing, Beijing.
Pulnovo Medical specializes in the development and production of innovative medical devices aimed at treating pulmonary hypertension. The company focuses on radiofrequency ablation technology, offering advanced solutions such as pulse radiofrequency ablation catheters and instruments. These pioneering products are designed to enhance the resilience and quality of life for patients suffering from pulmonary hypertension and heart failure. Pulnovo Medical holds global invention patents for its high-frequency ablation equipment and intravascular catheters, reflecting its commitment to advancing treatment methodologies in this critical area of healthcare.
Owlet Baby Care Inc. is a company that develops and manufactures innovative monitoring products designed to track the vital signs of sleeping infants. Founded in 2012 and based in Lehi, Utah, Owlet offers the Owlet Smart Sock, a device that monitors an infant's heart rate and oxygen levels, alerting parents if there are any concerns. The Owlet Baby Monitor provides real-time data on a child's vital signs through a compatible app for iOS and Android devices, giving parents peace of mind. The company's product range also includes the Owlet Cam, which transforms smartphones into high-definition baby monitors, and the Owlet Monitor Duo, which combines the features of the Smart Sock with the Cam. Additionally, the Owlet Dream Lab offers resources to help parents establish healthy sleep habits for their children. Owlet's commitment to enhancing parental confidence through technology is reflected in its diversified product portfolio.
Turnstone Biologics Inc., a biotechnology company, focuses on the development of viral immunotherapies to improve survival of people with cancer. Its lead candidate RIVAL-01 consists of the vaccinia virus backbone encoding three potent immunomodulators, such as Flt3 ligand, anti-CTLA-4 antibody, and IL-12 cytokine designed to work together to drive immune activity and re-program the microenvironment to be best suited for tumor eradication. The company was founded in 2015 and is based in Ottawa, Canada with an additional office in New York, New York.
Iambic Therapeutics focuses on accelerating molecular discovery through its innovative quantum molecular simulation engine. By integrating artificial intelligence and automated synthetic development, the company aims to enhance the design of small-molecule therapeutics. This technology significantly improves the accuracy of molecular predictions, providing valuable insights for therapeutic discovery. Iambic Therapeutics is committed to transforming the drug development process, enabling physicians to access more precise molecular data and ultimately improving treatment outcomes.
NeRRe Therapeutics Ltd. is a biotechnology company based in Stevenage, United Kingdom, established in 2012. The company specializes in the development of neurokinin (NK) receptor antagonists, focusing on treatments for conditions related to intense pruritus, particularly in patients undergoing targeted anti-cancer therapies. Its lead asset, orvepitant, is an oral NK-1 antagonist designed to alleviate this specific symptom. Additionally, NeRRe is advancing other candidates, including NT-814, a dual NK-1 and NK-3 antagonist, and NT-949, which is ready for Phase I trials. The company also has NT-432, a clinical candidate targeting NK-1 receptors. NeRRe Therapeutics aims to address unmet medical needs through its innovative therapeutic approaches.
Biocytogen is a biotechnology company specializing in the development of gene-engineered animal models for life sciences research. Founded in 2008 and headquartered in Beijing, with additional locations in the United States, Biocytogen offers a range of preclinical animal studies utilizing various advanced models, including gene humanized and patient-derived xenograft (PDX) models. Its product portfolio features numerous genetically modified mouse and rat models designed for research in areas such as tumor immunity, autoimmunity, and pharmacology. The company also provides customized gene-targeting services, phenotype analysis, and an antibody research and development platform. By integrating resources from both China and the U.S., Biocytogen aims to be a leading supplier of gene-targeted animal models and services globally.
Insilico Medicine, Inc. is an artificial intelligence company based in Rockville, Maryland, specializing in drug discovery, biomarker development, and aging research. Founded in 2014, the company leverages advanced AI techniques, including generative adversarial networks and deep learning, to create novel molecular structures for various diseases. Insilico Medicine has developed a comprehensive end-to-end pipeline for drug discovery, which encompasses all stages from initial research to clinical trials. Its notable platforms include Pharma.AI, which offers machine learning services to various sectors, and Young.AI, which integrates predictors of age. The company is actively engaged in internal drug discovery programs targeting conditions such as cancer, Alzheimer's disease, and diabetes. Additionally, Insilico Medicine has partnered with Life Extension to produce nutraceutical products using bioinformatics and deep learning. It serves a diverse clientele, including academia, pharmaceutical companies, and cosmetic firms, while also providing consumer-facing applications to enhance health and longevity.
RayzeBio, Inc. is a biotechnology company based in San Diego, California, founded in 2020. The company specializes in developing tumor-targeted small molecule medicines that utilize radioisotopes, particularly focusing on alpha-emitting isotopes like Actinium-225 for the treatment of solid tumors. RayzeBio aims to improve cancer treatment outcomes by creating a robust pipeline of radiopharmaceuticals targeting validated oncology drug targets. Its portfolio includes multiple drug candidates at various stages of development, ranging from discovery to late-stage clinical programs, addressing significant market opportunities in the field of cancer therapeutics.
Born from the founders’ recognition that their diverse but complementary skills and experiences would enable them to successfully address challenges that others had not, the company set about solving a vexing problem: how to bring true proteomics to the world in a way that accelerates therapeutic development, dramatically improves medical diagnostics, and makes personalized and predictive medicine a reality. The extraordinary team at Nautilus represents a wide spectrum of disciplines and expertise, including protein chemists, chip designers, molecular biologists, data scientists, material scientists, biophysicists, optical engineers, microfluidics engineers, bioinformaticists, software engineers, and more. Nautilus is positioned to revolutionize proteomics, transform the way drugs are developed, and significantly improve the way human health is managed.
Stemirna Therapeutics Co., Ltd. is a biotechnology company based in Shanghai, China, founded in 2016. The company specializes in developing mRNA technology-based drug solutions, with a focus on personalized cancer vaccines, mRNA vaccines for infectious diseases, and treatments for genetic and protein defect diseases. Stemirna has established a comprehensive mRNA drug platform that includes a GMP production center and a tumor neoantigen library, along with a clinical cooperation platform for mRNA drug development. With more than a dozen independently-developed projects, Stemirna aims to harness the potential of RNA science to provide safe and effective therapeutic options for patients suffering from various medical conditions.
Binx Health Limited is an in vitro diagnostics company based in Trowbridge, United Kingdom, specializing in the development of diagnostic instruments and disposable cartridge systems for decentralized laboratory and point-of-care environments. The company's flagship products include the io System, which detects infectious diseases such as chlamydia and MRSA, and Callisto, designed to accommodate various testing throughput requirements. Binx Health focuses on providing solutions for sexually transmitted infections and hospital-acquired infections. The company aims to enhance healthcare accessibility by delivering on-demand testing directly to consumers, utilizing its proprietary, desktop, PCR-based platforms and mobile offerings. Established in 2005, Binx Health has formed a strategic partnership with Sherlock Biosciences to further advance its innovative healthcare solutions.
Sparrow Pharmaceuticals, founded in 2013 and based in Portland, Oregon, focuses on developing targeted therapies for conditions related to corticosteroid excess. The company aims to provide innovative treatment options for disorders linked to elevated levels of cortisol, which can arise from tumors or prolonged use of corticosteroid medications like prednisone. By addressing serious issues associated with hypercortisolism, Sparrow Pharmaceuticals seeks to enhance the management of autoimmune and inflammatory conditions, ultimately improving patient care and outcomes in this challenging medical area.
Magenta is focused on improving the patient experience in transplant medicine, with the goal of bringing this lifesaving procedure to more patients. Over the past 50 years, stem cell transplantation has been used in more than 1M patients worldwide. It is currently the only treatment with the potential to cure some of the most devastating hematologic cancers and autoimmune diseases. Despite the increased use and clinical advancements over the past several decades, stem cell transplant remains a high-risk last-resort therapeutic option due to the toxicity and potential long-term side effects.
Caris Molecular Intelligence revolutionizes precision medicine to provide physicians and patients with information about their health. They develop Caris Molecular Intelligence Services that does panomic molecular profiling for oncology.
Caris Life Sciences was founded with a very simple but powerful purpose – to help improve the lives of as many people as possible. Through tireless efforts, breakthrough molecular science, and a passionate commitment to quality, they remain steadfastly focused on the most important part of their work – the patient.
It was founded in 1996 and is based in Irving, Texas.
Gennao Bio
Series A in 2021
Gennao Bio is a privately held genetic medicines company developing first-in-class targeted nucleic acid therapeutics utilizing a proprietary gene monoclonal antibody (GMAB) platform technology. GMAB is an adaptive technology that uses a novel, cell-penetrating antibody to non-covalently bind to and deliver therapeutic levels of a wide variety of nucleic acid payloads to select cells. This non-viral delivery platform is differentiated from traditional gene delivery systems as it can deliver multiple types of nucleic acids, allows for repeat dosing and employs well-established manufacturing processes. Gennao Bio is developing this delivery system with an initial focus on addressing significant unmet needs in oncology and rare monogenic skeletal muscle diseases.
Treeline Biosciences is a biotech company building transformative precision medicines for patients with cancer and other serious conditions. The company was founded in 2021 and is headquartered in Stamford, CT.
Janux Therapeutics develops immunotherapies that generate immune responses to prevent tumors and not affecting a patient’s healthy tissue. Janux technology targets all three stages of the anti-tumor immune response. Janux Therapeutics, Inc. was founded in 2017 by David Campbell and is based in La Jolla, California.
Invivyd is a biotechnology company focused on developing advanced antibodies to neutralize SARS-CoV-2, SARS-CoV-1, and other potentially emerging coronaviruses. Founded in 2020 and headquartered in Waltham, Massachusetts, the company aims to create best-in-class therapeutic and prophylactic treatments that surpass the efficacy of existing antibody programs. Its innovative portfolio features multiple non-competing antibodies, each targeting distinct viral epitopes, which is designed to minimize the risk of viral escape. By leveraging cutting-edge antibody discovery technologies, Invivyd seeks to enhance the potency and durability of its antibody candidates, addressing a critical need in the ongoing fight against coronaviruses.
Arrail Dental Clinic is specialized in providing oral health care services to its clients both home and abroad.
So far, Arrail has set up thirty branches in central business districts in first and second-tier cities in China such as Beijing, Shanghai, Shenzhen, Guangzhou, Xiamen, Hangzhou, and Tianjin. It also provides a broad platform for elite dentists all over the world.
Theseus Pharmaceuticals
Series B in 2021
Theseus Pharmaceuticals is a Technology based company.
Scribe Therapeutics Inc. engages in the engineering, delivery, and development of in vivo therapies and CRISPR molecules to rewrite and repair the underlying cause of genetic disorders. Its technology includes X-Editing (XE), an engineered molecule for therapeutic use and in vivo genetic modification. The company was incorporated in 2017 and is based in Berkeley, California.
Crossover Health, Inc. specializes in workplace healthcare services aimed at enhancing the health and well-being of employees. Founded in 2010 and headquartered in Aliso Viejo, California, the company operates health centers across the United States, including Silicon Valley. Crossover Health provides a comprehensive range of services, including primary and urgent care, preventive care, chronic disease management, and various ancillary services such as physical therapy and health coaching. By focusing on customized health solutions based on health analytics, Crossover Health collaborates with employers to optimize benefit design and enhance employee engagement in their health. This approach aims to transform traditional healthcare models by reducing costs and improving care quality, ultimately fostering a healthier, more motivated workforce.
NewMed Medical Co., Ltd. engages in the research, development, manufacture, and marketing of interventional artificial heart valve systems. Its products include artificial heart valves and transcather implantation systems. The company was founded in 2015 and is based in Shanghai, China.
X4 Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on developing innovative therapeutics for primary immune deficiencies and cancer. The company's lead drug candidate, mavorixafor, is an oral small molecule antagonist of the CXCR4 chemokine receptor, currently undergoing various clinical trials. Mavorixafor is in Phase III trials for treating patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome, and is also being tested in Phase Ib trials for severe congenital neutropenia and Waldenström macroglobulinemia, alongside a Phase IIa trial for clear cell renal cell carcinoma. Additionally, X4 Pharmaceuticals is advancing X4P-002, aimed at treating glioblastoma multiforme, and is developing X4P-003 for primary immune deficiencies. The company has established a license agreement with Abbisko Therapeutics to explore the use of mavorixafor in combination with checkpoint inhibitors for oncology applications. Founded in 2014, X4 Pharmaceuticals was previously known as Arsanis, Inc. before rebranding in March 2019.
At Graphite Bio, they are rapidly building a next-generation gene editing company that is driven to apply their breakthrough technology with urgency to advance gene replacement therapies and cures for people living with serious diseases. They stand apart through our ability to harness natural and highly precise cellular DNA repair machinery to achieve high efficiency, targeted gene integration to correct the underlying causes of diseases.
Century Therapeutics, Inc. is a biotechnology company focused on developing induced pluripotent stem cell (iPSC)-based therapies for cancer treatment. Founded in 2018 and headquartered in Philadelphia, Pennsylvania, the company aims to create allogeneic living drugs that specifically target both hematologic and solid tumors. By utilizing iPSCs, Century Therapeutics can engineer immune effector cells through multiple rounds of cellular modification, producing master cell banks that can be expanded and differentiated for therapeutic use. Their innovative approach incorporates advanced technologies such as CRISPR-mediated gene editing and proprietary chimeric antigen receptors, along with Allo-Evasion technology, which helps prevent rejection by the host immune system. These advancements position Century Therapeutics to enhance the effectiveness and accessibility of cancer treatments.
Janux Therapeutics develops immunotherapies that generate immune responses to prevent tumors and not affecting a patient’s healthy tissue. Janux technology targets all three stages of the anti-tumor immune response. Janux Therapeutics, Inc. was founded in 2017 by David Campbell and is based in La Jolla, California.
BlossomHill Therapeutics, Inc. is a small molecule drug discovery and development company focused on unmet medical needs in oncology and autoimmune disorders.
Yisheng Biopharma Co., Ltd., a biopharmaceutical company, researches, develops, manufactures, and markets immuno-oncology products and vaccines. It offers YS-ON-001, an investigational biological product that demonstrates immuno-modulating effects, such as induction of anti-tumor cytokines, activation of NK cells, regulation of macrophage polarization, and suppression of regulatory T cells for the treatment of advanced solid tumors. Yisheng Biopharma Co., Ltd. was founded in 2002 and is based in Beijing with operations in China, the United States, Cambodia, and Singapore.
Guangzhou Baseline Medical is committed to building a world-class clinical application of high-throughput sequencing and R & D platform to become the leading global provider of precision medical solutions. The company's core team has more than 20 years of senior industry experience, involved in cancer genomics, genetics and bioinformatics and other fields. Based on its core technical advantages, the Company aims at precision medicine, establishes a cooperative relationship with middle and downstream enterprises in the industry, and forms a complete industrial chain from academic research to clinical product transformation. It has also established close cooperation with many large-scale third-party inspection agencies including Illumina, Well-known domestic and foreign hospitals and research institutes to establish cooperative relations, the development of a series of independent intellectual property rights and international competitiveness of clinical testing products for patients, doctors and medical institutions to provide accurate, convenient and comprehensive services.
Clover Biopharmaceuticals is a clinical-stage biotechnology company based in Chengdu, China, focused on discovering and developing innovative biologic therapies for cancer, autoimmune diseases, and infectious diseases. Founded in 2007, the company utilizes its proprietary Trimer-Tag technology platform to create novel biologics that target trimerization-dependent pathways. Clover also offers integrated biopharmaceutical drug manufacturing services and has in-house capabilities for cGMP biomanufacturing, which support the development of select biosimilars. Through its research and development efforts, Clover aims to bring transformative therapies to the market.
Evox Therapeutics Limited develops a modular platform for clinical translation of exosome-based therapeutics. The company develops extracellular vesicles-based nucleic acid and protein delivery technology. Its technology aims to hitch a ride on tiny particles called exosomes, which the body uses to transport molecules between cells. Evox Therapeutics Limited was founded in 2016 and is based in Oxford, United Kingdom.
Miaoshou Doctor is a healthcare service platform for building an online communication service platform between patients and doctors. It helps healthcare professionals and patients to manage post-diagnosis outcomes and allows doctors to actively follow up with their patient's health through additional counseling and prescriptions. Tao He and Daoliang Han founded the company in 2015 and is based in Beijing, Beijing.
Gemini Therapeutics, Inc. is a precision medicine company established in 2015 and based in Cambridge, Massachusetts. The company specializes in developing therapies for patients with dry age-related macular degeneration (AMD) and related rare genetic diseases. Gemini's approach focuses on addressing genetically-defined conditions by creating therapeutic candidates that target specific molecular abnormalities prevalent in patients with significant clinical needs. Their diverse pipeline features a range of innovative treatment modalities, including monoclonal antibodies, recombinant proteins, and gene therapies. The company has secured funding from prominent life science investors and collaborates with academic institutions globally to advance its mission of delivering potentially first-in-class therapeutics.
Delfi Diagnostics, Inc. is a biotechnology company based in Baltimore, Maryland, that specializes in early cancer detection through non-invasive blood tests. Founded in 2018, the company utilizes advanced artificial intelligence and genome sequencing technologies to identify unique patterns of DNA fragmentation in patients' blood, enabling the detection of cancer at its most treatable stage. By focusing on precision diagnostics, Delfi Diagnostics aims to improve patient outcomes and contribute to the evolving landscape of cancer care.
Noctrix Health, Inc. is an early-stage medical device company based in Menlo Park, California, founded in 2018. The company specializes in the development of therapeutic wearable devices aimed at treating chronic neurological and sleep disorders. By focusing on innovative therapies, Noctrix Health seeks to address the unmet needs of patients suffering from these conditions.
Visen Pharmaceuticals is a biotech company focused on developing and commercializing innovative endocrine drugs that address significant unmet needs for patients in Greater China.
Scorpion Therapeutics, Inc. is a biotechnology company based in Boston, Massachusetts, focused on developing advanced precision oncology therapies for cancer treatment. Founded in 2020, the company aims to enhance the accessibility and effectiveness of precision medicine for cancer patients. Scorpion Therapeutics specializes in creating drugs in three primary areas: therapies targeting known oncogenes, agents for currently undruggable cancer targets, and innovative drugs for new targets. By integrating state-of-the-art technologies in target discovery, medicinal chemistry, and translational medicine, the company is committed to delivering next-generation precision oncology solutions. Its experienced leadership team is dedicated to employing a tailored approach to efficiently advance the field of precision cancer treatment.
Abbisko Therapeutics Co. Ltd. discovers, develop, and manufactures immuno-oncology therapies. It offers ABSK011 and ABSK021, which are molecule inhibitors for treating hepatocellular carcinoma; and CSF1R for the treatment of solid tumors. The company also develops therapeutics for the treatment of cancer, tumor, and diabetes, metabolic diseases, liver diseases, viral infections and CNS diseases. The company was founded in 2016 and is based in is based in Shanghai, China.
Terns Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering and developing molecularly targeted, oral small-molecule drugs aimed at treating cancer and liver diseases. Founded in 2017 and headquartered in Foster City, California, with additional offices in Shanghai, China, Terns leverages its expertise in disease biology and medicinal chemistry to advance its drug pipeline. Notable products include TERN-101, a potent farnesoid X receptor agonist, and TERN-201, a semicarbazide-sensitive amine oxidase inhibitor. The company emphasizes a capital-efficient drug discovery model and has extensive clinical development capabilities in China, striving to bring innovative therapeutic candidates to address significant unmet medical needs both locally and globally.